drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous anti-FGFR2b antibody–drug conjugate that binds FGFR2b on tumor cells, is internalized, and releases an intracellular cytotoxic payload to induce tumor cell death; targeting may also attenuate FGFR2 signaling. Evaluated as monotherapy and in combination with other anticancer agents in advanced solid tumors with FGFR2b expression and/or FGFR2 amplification.
nci_thesaurus_concept_id
C210962
nci_thesaurus_preferred_term
Anti-FGFR2b/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C137
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the fibroblast growth factor receptor 2b (FGFR2b; fibroblast growth factor receptor 2 isoform IIIb; FGFR2 IIIb) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-FGFR2b/topoisomerase-1 inhibitor ADC BG-C137, the antibody moiety targets and binds to FGFR2b-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FGFR2b. FGFR2b is overexpressed on certain tumor cell types.
drug_mesh_term
Antineoplastic Agents
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
BG-C137 is an anti-FGFR2b monoclonal antibody linked to a topoisomerase-1 inhibitor. After binding FGFR2b on tumor cells and internalization, it releases the cytotoxic payload that inhibits DNA topoisomerase I, disrupting DNA replication and causing cell cycle arrest and apoptosis; target binding may also attenuate FGFR2 signaling.
drug_name
BG-C137
nct_id_drug_ref
NCT06625593